An Open Label, Single-Centre, Phase II Study for Radiosensitization of Everolimus With External Beam Radiotherapy for the Treatment of Metastatic Neuroendocrine Liver Metastasis

Trial Profile

An Open Label, Single-Centre, Phase II Study for Radiosensitization of Everolimus With External Beam Radiotherapy for the Treatment of Metastatic Neuroendocrine Liver Metastasis

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Jul 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Liver metastases; Neuroendocrine tumours
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms EBRT
  • Most Recent Events

    • 22 Jul 2016 Status changed from not yet recruiting to recruiting.
    • 29 Feb 2016 Planned number of patients changed from 10 to 14 as reported by ClinicalTrials.gov record.
    • 29 Feb 2016 Planned End Date changed from 1 Sep 2019 to 1 Mar 2020 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top